JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 214 filers reported holding JUNO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.99 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $4,286,000 | -2.9% | 93,773 | -4.7% | 0.01% | 0.0% |
Q3 2017 | $4,413,000 | +1.4% | 98,399 | -32.4% | 0.01% | -16.7% |
Q2 2017 | $4,354,000 | +29.9% | 145,663 | -3.6% | 0.01% | +33.3% |
Q1 2017 | $3,351,000 | +21.1% | 151,030 | +2.9% | 0.01% | +12.5% |
Q4 2016 | $2,766,000 | -29.7% | 146,738 | +11.9% | 0.01% | -33.3% |
Q3 2016 | $3,936,000 | -11.3% | 131,150 | +13.6% | 0.01% | -14.3% |
Q2 2016 | $4,436,000 | +1.6% | 115,404 | +0.7% | 0.01% | 0.0% |
Q1 2016 | $4,364,000 | +5.5% | 114,570 | +21.7% | 0.01% | +16.7% |
Q4 2015 | $4,138,000 | +341.6% | 94,109 | +308.9% | 0.01% | +300.0% |
Q3 2015 | $937,000 | -90.3% | 23,017 | -87.3% | 0.00% | -87.5% |
Q2 2015 | $9,637,000 | +111.0% | 180,703 | +140.0% | 0.02% | +118.2% |
Q1 2015 | $4,568,000 | – | 75,300 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
SIB LLC | 100,000 | $3,001,000 | 2.42% |
Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
First Washington CORP | 65,320 | $1,960,000 | 1.10% |
PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |